Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

Tretinoin alone has led to hair regrowth in the temples and hairline. The user is considering oral minoxidil or dutasteride but prioritizes health first.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

A user with aggressive androgenic alopecia is considering increasing their dutasteride dose from 0.5 mg to potentially 2.5 mg, while already using oral minoxidil, Nizoral, RU-58841, and dermapen. They are seeking advice on the effectiveness and side effects of higher dutasteride doses, with suggestions to consult a dermatologist and consider a higher Nizoral concentration.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.

The conversation is about the release date of pyrilutamide for hair loss treatment. No specific release date is provided.

The conversation discusses using tretinoin as an additional treatment for hair loss alongside minoxidil, with plans to test its effectiveness by applying it to only one side of the scalp. The user intends to start this experiment after using minoxidil for a year.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

The user added 0.5mg dutasteride to their regimen of topical finasteride and minoxidil but experienced rapid hairline recession despite reduced hair fall. Suggestions included increasing the dutasteride dosage to 1mg daily to better suppress DHT and potentially adding oral minoxidil.

A user shared their two-month progress using dutasteride, minoxidil, ketoconazole shampoo, and tretinoin cream for hair loss, reporting no side effects and increased sex drive. Other users discussed their experiences with similar treatments, including finasteride and oral minoxidil, and debated the effectiveness of microneedling.

The user started a hair care routine using 0.5mg finasteride daily, 2ml of 5% minoxidil, and 4.5mg of cetirizine topically to address hair loss. They plan to provide updates and are also interested in cetirizine's potential to reduce scalp itching and redness due to its anti-inflammatory properties.

The discussion revolves around the need for future oral DHT blockers for hair loss treatment that don't have the side effects of current options like Finasteride and Dutasteride. One user suggests that the future of hair loss treatment will likely be topical anti-androgens, as they can target hair follicles without affecting the entire system.

User found hair loss stabilization without side effects using a topical solution of 0.008% Finasteride, 2% RU, and Stemoxydine. Other treatments like Eucapil, Fluridil, RU-monotherapy, and Pyrilutamide didn't work for them.

The user experienced hair regrowth using finasteride, oral and topical minoxidil, and RU58841, despite initial shedding. They also transitioned from finasteride to dutasteride and addressed scalp issues with a folliculitis shampoo.

Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

A user is combining RU58841 with a topical formula containing finasteride, dutasteride, minoxidil, triamcinolone, caffeine, and other ingredients. They have just started using it and report no side effects so far.

The user is currently using alfatradiol and fluridil for hair loss and is considering adding low-dose topical finasteride but is concerned about potential side effects due to past mental health issues. They are seeking others' experiences with these treatments and their effectiveness.

The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.

The conversation discusses hair loss treatments, specifically progesterone therapy with hydrocortisone butyrate, and the use of dutasteride and finasteride. Opinions vary on the effectiveness and side effects of these treatments, with some users advocating for acceptance of balding if treatments are not suitable.

A user reports significant hair density increase and new growth at the temples after two months of using finasteride, minoxidil, ketoconazole, dermarolling, MK-677, zinc, and vitamin D3, with shedding stopping a week ago. They recently added MK-677 to their regimen.

Fluridil, an antiandrogen that is not widely used or known about due to its expense and lack of availability in the US. It is suggested as a potential alternative for people who don't want to lower their DHT through treatments such as Minoxidil, Finasteride, Nizoral shampoo, and Dermarolling.

The conversation discusses managing hair loss and scalp issues, with users sharing experiences using treatments like dutasteride, finasteride, ketoconazole, sulfur soap, and topical anti-androgens. Suggestions include trying sulfur soap, scalp massages, spironolactone, and dietary changes to reduce sebum production and dandruff.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

An 18-year-old is using a high-dose hair loss treatment with 40mg daily dutasteride, finasteride, minoxidil, tretinoin, and topical bicalutamide. Despite health risk concerns, especially liver issues, they report hair regrowth progress and intend to continue the regimen.

The conversation is about adding crushed bicalutamide or spironolactone to a topical mix with finasteride and minoxidil to suppress testosterone in hair follicles, similar to what RU58841 does. The user cannot obtain RU58841 in their country and is seeking advice on this alternative approach for hair loss treatment.

The user is using a hair regrowth protocol including dutasteride, topical and oral minoxidil, dermarolling, ketoconazole shampoo, and tretinoin, but is experiencing slow progress and seeks advice for faster regrowth. Suggestions include quitting smoking, adjusting the regimen, and considering additional treatments like topical finasteride or RU58841.

The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.

A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.